A detailed history of Columbia Asset Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Columbia Asset Management holds 9,538 shares of LLY stock, worth $7.69 Million. This represents 1.61% of its overall portfolio holdings.

Number of Shares
9,538
Previous 9,065 5.22%
Holding current value
$7.69 Million
Previous $5.28 Million 63.44%
% of portfolio
1.61%
Previous 1.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$724.87 - $909.04 $342,863 - $429,975
473 Added 5.22%
9,538 $8.64 Million
Q1 2024

May 08, 2024

BUY
$592.2 - $792.28 $8,883 - $11,884
15 Added 0.17%
9,065 $5.28 Million
Q4 2023

Feb 09, 2024

BUY
$525.19 - $619.13 $129,721 - $152,925
247 Added 2.81%
9,050 $5.28 Million
Q3 2023

Nov 13, 2023

BUY
$434.7 - $599.3 $445,567 - $614,282
1,025 Added 13.18%
8,803 $4.73 Million
Q2 2023

Aug 14, 2023

BUY
$350.74 - $468.98 $1.19 Million - $1.59 Million
3,389 Added 77.22%
7,778 $3.65 Million
Q3 2022

Nov 03, 2022

BUY
$296.48 - $337.87 $29,648 - $33,787
100 Added 2.33%
4,389 $1.42 Million
Q2 2021

Aug 02, 2021

SELL
$180.55 - $233.54 $76,011 - $98,320
-421 Reduced 8.94%
4,289 $984,000
Q3 2020

Nov 16, 2020

SELL
$146.22 - $169.13 $10,966 - $12,684
-75 Reduced 1.57%
4,710 $697,000
Q2 2020

Aug 14, 2020

BUY
$136.42 - $164.18 $2,728 - $3,283
20 Added 0.42%
4,785 $786,000
Q3 2019

Nov 12, 2019

SELL
$106.79 - $116.16 $2,669 - $2,904
-25 Reduced 0.52%
4,765 $533,000
Q4 2018

Feb 12, 2019

SELL
$105.9 - $118.64 $5,083 - $5,694
-48 Reduced 0.99%
4,790 $554,000
Q3 2018

Nov 06, 2018

BUY
$85.86 - $107.31 $4,121 - $5,150
48 Added 1.0%
4,838 $519,000
Q1 2018

May 07, 2018

SELL
$74.21 - $87.6 $20,778 - $24,528
-280 Reduced 5.52%
4,790 $371,000
Q3 2017

Nov 07, 2017

BUY
$77.07 - $85.54 $390,744 - $433,687
5,070
5,070 $434,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $766B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Columbia Asset Management Portfolio

Follow Columbia Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Columbia Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Columbia Asset Management with notifications on news.